<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097850</url>
  </required_header>
  <id_info>
    <org_study_id>NU 09D1</org_study_id>
    <nct_id>NCT01097850</nct_id>
  </id_info>
  <brief_title>Topical Henna Preparation for the Treatment of Hand Foot Skin Syndrome</brief_title>
  <official_title>Prospective Randomized Controlled Open-label Trial of a Topical Henna Preparation for the Treatment of Hand-Foot Skin Syndrome and Its Associated Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether henna paste is effective in the treatment
      of hand-foot skin syndrome, induced by the drugs Capecitabine and pegylated liposomal
      doxorubicin.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subject accrual.
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• To compare the severity of HFS in subjects receiving topical natural henna paste treatment along with using CeraVe™ moisturizing cream concurrently on the treatment side and using only CeraVe™ moisturizing cream on the control side.</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine quality of life, comparing natural henna treatment versus CeraVe™ alone, using the Skindex-16 questionnaire</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hand Foot Skin Syndrome</condition>
  <arm_group>
    <arm_group_label>Right</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Application of henna paste to right hand/foot plus CeraVe moisturizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Left</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Application of henna paste to the left hand/foot plus CeraVe moisturizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>henna paste</intervention_name>
    <description>Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet</description>
    <arm_group_label>Right</arm_group_label>
    <arm_group_label>Left</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving capecitabine and/or pegylated liposomal doxorubicin as monotherapy
             or in combination with other agents

          -  New diagnosis of active hand-foot skin reaction (on bilateral hands and/or bilateral
             feet) of 1-3 toxicity as defined by the NCI-CTCAE version 4.0 grading scale with onset
             of symptoms within the last thirty days

          -  Patients must be 18 years or older

          -  Patients must provide written informed consent to participate in the study

        Exclusion Criteria:

          -  Patients with pre-existing dermatological condition affecting the hands or feet that
             may limit the interpretation of results

          -  Known allergy to natural henna

          -  Patients with a previous history of HFS

          -  History of G6PD deficiency as determined by screening bloodwork
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Lio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>April 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Dennis West</investigator_full_name>
    <investigator_title>Professor in Dermatology and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>hand foot skin syndrome</keyword>
  <keyword>palmar plantar erythrodysesthesia</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lawsone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

